Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,578
archived clinical trials in
Skin and Soft Tissue Infections

Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis
Status: Archived
Children's Memorial Hospital, Chicago
1730
mi
from 98109
Chicago, IL
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis
Status: Archived
Updated: 1/1/1970
Children's Memorial Hospital, Chicago
1730
mi
from 98109
Chicago, IL
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial
Status: Archived
Northwestern University
1733
mi
from 98109
Chicago, IL
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial
Status: Archived
Updated: 1/1/1970
Northwestern University
1733
mi
from 98109
Chicago, IL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
University of Alabama at Birmingham
2080
mi
from 98109
Birmingham, AL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
University of Alabama at Birmingham
2080
mi
from 98109
Birmingham, AL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Children's Hospital San Diego & University of California San Diego
1060
mi
from 98109
San Diego, CA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Children's Hospital San Diego & University of California San Diego
1060
mi
from 98109
San Diego, CA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Stanford university Hospital and Clinics
705
mi
from 98109
Stanford, CA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
705
mi
from 98109
Stanford, CA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
University of Miami Hospital
2730
mi
from 98109
Miami, FL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
2730
mi
from 98109
Miami, FL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Northwestern University Feinberg School of Medicine Dept of Dermatology
1730
mi
from 98109
Chicago, IL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Northwestern University Feinberg School of Medicine Dept of Dermatology
1730
mi
from 98109
Chicago, IL
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
University of Massachusetts Worcester
2454
mi
from 98109
Worcester, MA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
University of Massachusetts Worcester
2454
mi
from 98109
Worcester, MA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Washington University
1717
mi
from 98109
St. Louis, MO
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Washington University
1717
mi
from 98109
St. Louis, MO
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
2154
mi
from 98109
Rochester, NY
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
2154
mi
from 98109
Rochester, NY
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
St Vincent Health Center
2076
mi
from 98109
Erie, PA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
St Vincent Health Center
2076
mi
from 98109
Erie, PA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Virginia Clinical Research, Inc.
2429
mi
from 98109
Norfolk, VA
Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa
Status: Archived
Updated: 1/1/1970
Virginia Clinical Research, Inc.
2429
mi
from 98109
Norfolk, VA
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis
Status: Archived
Loyola University Medical Center
1724
mi
from 98109
Proviso, IL
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis
Status: Archived
Updated: 1/1/1970
Loyola University Medical Center
1724
mi
from 98109
Proviso, IL
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Veterans Affairs Medical Center - Lakeside Chicago
1732
mi
from 98109
Chicago, IL
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - Lakeside Chicago
1732
mi
from 98109
Chicago, IL
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
VA Medical Center, Augusta
2299
mi
from 98109
Augusta, GA
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Updated: 1/1/1970
VA Medical Center, Augusta
2299
mi
from 98109
Augusta, GA
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Edward Hines,Jr., VA Hospital
1724
mi
from 98109
Hines, IL
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Updated: 1/1/1970
Edward Hines,Jr., VA Hospital
1724
mi
from 98109
Hines, IL
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
1720
mi
from 98109
St Louis, MO
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Updated: 1/1/1970
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
1720
mi
from 98109
St Louis, MO
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Veterans Affairs Medical Center - East Orange
2391
mi
from 98109
East Orange, NJ
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - East Orange
2391
mi
from 98109
East Orange, NJ
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Zablocki VA Medical Center, Milwaukee
1684
mi
from 98109
Milwaukee, WI
Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)
Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury
Status: Archived
Updated: 1/1/1970
Zablocki VA Medical Center, Milwaukee
1684
mi
from 98109
Milwaukee, WI
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Status: Archived
University of California, Davis Department of Dermatology
627
mi
from 98109
Sacramento, CA
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
University of California, Davis Department of Dermatology
627
mi
from 98109
Sacramento, CA
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status: Archived
Children's Medical Center of Dallas
1676
mi
from 98109
Dallas, TX
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status: Archived
Updated: 1/1/1970
Children's Medical Center of Dallas
1676
mi
from 98109
Dallas, TX
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status: Archived
Children's Hospital Central California
745
mi
from 98109
Madera, CA
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status: Archived
Updated: 1/1/1970
Children's Hospital Central California
745
mi
from 98109
Madera, CA
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status: Archived
Morgan Stanley Children's Hospital
2400
mi
from 98109
New York, NY
Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status: Archived
Updated: 1/1/1970
Morgan Stanley Children's Hospital
2400
mi
from 98109
New York, NY
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash
Status: Archived
University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash
Status: Archived
Updated: 1/1/1970
University of Pittsburgh Medical Center
2134
mi
from 98109
Pittsburgh, PA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Southbay Pharma Research
979
mi
from 98109
Buena Park, CA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Southbay Pharma Research
979
mi
from 98109
Buena Park, CA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
eStudySite
1074
mi
from 98109
Chula Vista, CA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
eStudySite
1074
mi
from 98109
Chula Vista, CA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Healthcare Partners Medical Group
975
mi
from 98109
Carson, CA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Healthcare Partners Medical Group
975
mi
from 98109
Carson, CA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Central Florida Internists
2564
mi
from 98109
St Cloud, FL
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Central Florida Internists
2564
mi
from 98109
St Cloud, FL
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Ronald Barbour, MD
2525
mi
from 98109
Temple Terrace, FL
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Ronald Barbour, MD
2525
mi
from 98109
Temple Terrace, FL
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Southeastern Regional Research Group
2205
mi
from 98109
Columbus, GA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Southeastern Regional Research Group
2205
mi
from 98109
Columbus, GA
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
eStudySite
876
mi
from 98109
Las Vegas, NV
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
eStudySite
876
mi
from 98109
Las Vegas, NV
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Ravi Kamepalli, MD
1932
mi
from 98109
Lima, OH
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Ravi Kamepalli, MD
1932
mi
from 98109
Lima, OH
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Health Concepts
944
mi
from 98109
Rapid City, SD
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Health Concepts
944
mi
from 98109
Rapid City, SD
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Jennifer Johnson-Caldwell, MD
1891
mi
from 98109
Houston, TX
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Jennifer Johnson-Caldwell, MD
1891
mi
from 98109
Houston, TX
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Alan Nolasco, MD
1890
mi
from 98109
Houston, TX
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
Status: Archived
Updated: 1/1/1970
Alan Nolasco, MD
1890
mi
from 98109
Houston, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Allergy, Asthma & Immunology, Assoc, Ltd.
1117
mi
from 98109
Scottsdale, AZ
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Allergy, Asthma & Immunology, Assoc, Ltd.
1117
mi
from 98109
Scottsdale, AZ
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
UCLA Medical Center
959
mi
from 98109
Los Angeles, CA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
UCLA Medical Center
959
mi
from 98109
Los Angeles, CA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Donald S. Levy, M.D.
984
mi
from 98109
Orange, CA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Donald S. Levy, M.D.
984
mi
from 98109
Orange, CA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Family Allergy and Asthma Center
2174
mi
from 98109
Atlanta, GA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Family Allergy and Asthma Center
2174
mi
from 98109
Atlanta, GA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Institute for Asthma and Allergy
2316
mi
from 98109
Wheaton, MD
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Institute for Asthma and Allergy
2316
mi
from 98109
Wheaton, MD
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
University of Cincinnati Medical Center
1963
mi
from 98109
Cincinnati, OH
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
University of Cincinnati Medical Center
1963
mi
from 98109
Cincinnati, OH
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Baker Allergy, Asthma and Dermatology Research Center
154
mi
from 98109
Lake Oswego, OR
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Baker Allergy, Asthma and Dermatology Research Center
154
mi
from 98109
Lake Oswego, OR
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Mark J. Florian, MD, PA
1805
mi
from 98109
Bryan, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Mark J. Florian, MD, PA
1805
mi
from 98109
Bryan, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
AARA Research Center
1678
mi
from 98109
Dallas, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
AARA Research Center
1678
mi
from 98109
Dallas, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Allergy and Asthma Research Center
1780
mi
from 98109
San Antonio, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Allergy and Asthma Research Center
1780
mi
from 98109
San Antonio, TX
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Marycliff Allergy Specialist
228
mi
from 98109
Spokane, WA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Marycliff Allergy Specialist
228
mi
from 98109
Spokane, WA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Puget Sound Allergy, Asthma & Immunology
27
mi
from 98109
Tacoma, WA
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks.
Status: Archived
Updated: 1/1/1970
Puget Sound Allergy, Asthma & Immunology
27
mi
from 98109
Tacoma, WA